Thomas Gad | Founder, Chairman & President |
Claus Møller | Chief Executive Officer |
Bo Kruse | Chief Financial Officer |
Alec Stranahan | Bank of America |
Charles Zhu | Guggenheim Securities |
Mike Ulz | Morgan Stanley |
Joseph Thome | Cowen & Company |
Tessa Romero | JPMorgan |
Sebastiaan van der Schoot | Kempen |
Good day and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the Fiscal Full Year of 2021. Today's conference is being recorded.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties that are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's annual report on Form 10-K for the fiscal year ended December 31, 2021, as filed with SEC on February 24, 2022. At this time, I would like to turn the conference over to Thomas Gad, the company's Founder, Chairman and President.